Yikes, bedbugs! EPA looks to stop resurgence

ARLINGTON, Va. – "Don't let the bedbugs bite." Doesn't seem so bad in a cheerful bedtime rhyme, but it's becoming a really big problem now that the nasty critters are invading hospitals, college dorms and even swanky hotels. With the most effective pesticides banned, the government is trying to figure out how to respond to the biggest bedbug outbreak since World War II.

Bedbugs live in the crevices and folds of mattresses, sofas and sheets. Then, most often before dawn, they emerge to feed on human blood.

Faced with rising numbers of complaints to city information lines and increasingly frustrated landlords, hotel chains and housing authorities, the Environmental Protection Agency hosted its first-ever bedbug summit Tuesday.

Organized by one of the agency's advisory committees, the two-day conference drew about 300 participants to a hotel in Arlington, just across the Potomac River from Washington. An Internet site notes that the hotel in question has had no reports of bedbugs.

One of the problems with controlling the reddish-brown insects, according to researchers and the pest control industry, is that there are few chemicals on the market approved for use on mattresses and other household items that are effective at controlling bedbug infestations.

Unlike roaches and ants, bedbugs are blood feeders and can't be lured by bait. It's also difficult for pesticides to reach them in every crack and crevice they hide out in.

"It is a question of reaching them, finding them," said Harold Harlan, an entomologist who has been raising bedbugs for 36 years, feeding them with his own blood. He has the bites to prove it.

The EPA, out of concern for the environment and the effects on public health, has pulled many of the chemicals that were most effective in eradicating the bugs in the U.S. At the same time, the appleseed-sized critters have developed a pesticide resistance because those chemicals are still in use in other countries.

Increasing international travel has also helped them to hitchhike into the U.S.

"One of our roles would be to learn of new products or safer products. ... What we are concerned about is that if people take things into their own hands and start using pesticides on their mattresses that aren't really registered for that, that's a problem," said Lois Rossi, director of the registration division in the EPA's Office of Pesticide Programs.

The EPA is not alone in trying to deal with the problem. An aide to Rep. G.K. Butterfield, D-N.C., says the congressman plans to reintroduce legislation next week to expand grant programs to help public housing authorities cope with infestations.

The bill will be called the "Don't Let the Bedbugs Bite Act."

"It was clear something needed to be done," said Saul Hernandez, Butterfield's legislative assistant.

Bedbugs are not known to transmit any diseases. But their bites can cause infections and allergic reactions in some people. The insects release an anticoagulant to get blood flowing, and they also excrete a numbing agent so their bites don't often wake their victims.

Those often hardest hit are the urban poor, who cannot afford to throw out all their belongings or take other drastic measures. Extermination can cost between $400-$900.

So bedbug problems increase, said Dini Miller, an entomologist and bedbug expert at Virginia Tech, who until 2001 saw bedbugs only on microscope slides dating from the 1950s. Now she gets calls and e-mails several times a day from people at their wits' end.

"I can't tell you how many people have spent the night in their bathtubs because they are so freaked out by bedbugs," Miller said. "I get these people over the phone that have lost their marbles."

Because the registration of new pesticides takes so long, one thing the EPA could do is to approve some pesticides for emergency use, Miller said.

Another tactic would be to screen pesticides allowed for use by farmers to see if they are safe in household settings.

Representatives of the pest control industry will be pushing for federal funding for research into alternative solutions, such as heating, freezing or steaming the bugs out of bedrooms.

"We need to have better tools," said Greg Baumann, a senior scientist at the National Pest Management Association. "We need EPA to consider all the options for us."

___

On the Net:

Harvard School of Public Health: http://www.hsph.harvard.edu/bedbugs/

University of Kentucky Insect Advice: http://www.ca.uky.edu/entomology/entfacts/ef636.asp

news source of www.news.yahoo.com

..read more...

Company says prostate cancer vaccine shows promise

An experimental treatment that takes an entirely new approach to fighting prostate cancer extended survival in a late-stage study, its maker announced Tuesday.

Seattle-based Dendreon Corp. said that its Provenge cancer vaccine improved overall survival when compared to a dummy treatment in a study of 512 men with advanced disease.

No survival details or information on side effects were given. Full results will be presented at an American Urological Association meeting later this month, and Dendreon said it would seek federal approval of the treatment later this year.

Provenge is not like traditional vaccines that prevent disease. It's a so-called therapeutic vaccine that treats cancer by training the immune system to fight tumors. If approved, Provenge would be the first such treatment on the market.

This is the second major study in which Provenge has shown a survival benefit, leading some scientists to hope not just for its approval but for a new approach to fighting cancer beyond the surgery, radiation, hormones and chemotherapy used now.

"This is an exciting result, demonstrating that harnessing a patient's own immune system can successfully attack prostate cancer," said Dr. Eric Small, cancer specialist at the University of California at San Francisco. "Now we have more confidence that the initial results we saw were real."

He enrolled some patients in the new study and led the earlier one, but has no financial ties to the company or the vaccine.

In the earlier study of 127 men, those treated with the vaccine lived an average of 4 1/2 months longer than those given dummy treatments. After three years, survival was 34 percent in the vaccine group and only 11 percent in the other.

Those results led advisers to the Food and Drug Administration to recommend Provenge's approval two years ago. But the FDA delayed action and asked for more data, because extending survival wasn't the main goal of that study — slowing progression of the cancer was, and the vaccine failed to do that.

The decision sparked protests from men's groups and cancer advocates because the vaccine did prolong survival, which they considered a more important result.

On Tuesday, results of the new study boosted Dendreon stock by $9.69, closing at $16.99, more than doubling in value as investors bet on improved chances of FDA approval and the potential for a lucrative market.

Provenge is a treatment that is customized for each patient. Doctors collect specialized cells from each patient's blood. Those cells help the immune system recognize cancer as a threat, much as it would germs that enter the body.

The cells are mixed with a protein found on most prostate cancer cells to help activate the immune system. The resulting "vaccine" is given back to the patient as three infusions two weeks apart.

So far, the vaccine has been tested on men with cancer that has spread beyond the prostate and is no longer responding to hormone treatments to curb its growth.

If Provenge proves safe and wins approval, "it would be an important breakthrough," said Dr. William Oh, a cancer specialist at Dana-Farber Cancer Center in Boston. Three years ago, he consulted for Dendreon on the vaccine but has had no financial ties to it since then.

"There are so few treatments available" for men whose prostate cancer has spread widely — a situation that affects 40,000 to 60,000 American men, he said.

Prostate cancer is the most common non-skin cancer in American men. An estimated 186,000 new cases and 28,660 deaths from it occurred last year.

news source of www.news.yahoo.com

..read more...